Hans-Willi Krell Selected Research

Carcinogenesis

1/2005

Reduction of alachlor-induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor Ro 28-2653.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Willi Krell Research Topics

Disease

12	Neoplasms (Cancer) 01/2009 - 03/2002
4	Prostatic Neoplasms (Prostate Cancer) 02/2007 - 03/2002
3	Neoplasm Metastasis (Metastasis) 09/2007 - 04/2002
2	Carcinoma (Carcinomatosis) 01/2009 - 02/2007
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 12/2011
1	Inflammation (Inflammations) 12/2009
1	Infections 12/2009
1	Ileitis 12/2009
1	Arthritis (Polyarthritis) 01/2006
1	Leukemia 01/2006
1	Carcinogenesis 01/2005
1	Atherosclerosis 08/2004
1	Adenocarcinoma 06/2004
1	Necrosis 03/2004
1	Rupture 12/2003
1	Choroidal Neovascularization 12/2003
1	Macular Degeneration (Age-Related Maculopathy) 12/2003
1	T-Cell Lymphoma (Lymphoma, T Cell) 10/2002
1	Fibrosarcoma 04/2002

Drug/Important Bio-Agent (IBA)

9	Matrix Metalloproteinases (MMPs)IBA 09/2007 - 03/2002
8	Matrix Metalloproteinase InhibitorsIBA 02/2007 - 03/2002
6	Ro 28-2653IBA 02/2007 - 03/2002
3	EnzymesIBA 01/2006 - 04/2002
2	AntibodiesIBA 12/2011 - 01/2009
2	GelatinasesIBA 12/2009 - 10/2002
2	Estramustine FDA Link 02/2007 - 09/2005
2	pyrimidineIBA 09/2005 - 06/2004
2	batimastat (BB 94)IBA 06/2004 - 03/2004
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 12/2003 - 04/2002
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 02/2003 - 04/2002
1	GW 4869IBA 12/2011
1	Interleukin-22 (IL-22)IBA 12/2009
1	Interleukin-23 (Interleukin 23)IBA 12/2009
1	CytokinesIBA 12/2009
1	Interleukin-17 (Interleukin 17)IBA 12/2009
1	matriptaseIBA 01/2009
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2009
1	Tissue Inhibitor of Metalloproteinase-1IBA 09/2007
1	DisintegrinsIBA 09/2007
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2007
1	Peptide Hydrolases (Proteases)FDA Link 09/2007
1	Etoposide (VP 16)FDA LinkGeneric 02/2007
1	Pharmaceutical PreparationsIBA 02/2007
1	AndrogensIBA 02/2007
1	ADAM17 ProteinIBA 01/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2006
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2006
1	Neutralizing AntibodiesIBA 01/2006
1	diphenyl (biphenyl)IBA 09/2005
1	Hormones (Hormone)IBA 09/2005
1	HerbicidesIBA 01/2005
1	alachlorIBA 01/2005
1	oxidized low density lipoproteinIBA 08/2004
1	Angiogenesis InhibitorsIBA 06/2004
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 03/2004
1	EndopeptidasesIBA 03/2004
1	Hydroxamic Acids (Hydroxamic Acid)IBA 03/2004
1	Protease Inhibitors (Protease Inhibitor)IBA 03/2004
1	Proteins (Proteins, Gene)FDA Link 03/2004
1	Sulfhydryl Compounds (Thiols)IBA 03/2004
1	ZincIBA 03/2004
1	Captopril (Capoten)FDA LinkGeneric 03/2004
1	TAPI-2IBA 03/2004
1	prolyl-leucyl-glycine hydroxamateIBA 03/2004
1	Metalloproteases (Metalloproteinases)IBA 03/2004
1	N- (2(R)- 2- (hydroxamidocarbonylmethyl)- 4- methylpentanoyl)- L- tryptophan methylamideIBA 03/2004
1	astacinIBA 03/2004
1	Tiopronin (Thiola)FDA Link 03/2004
1	GelatinIBA 02/2003
1	Biomarkers (Surrogate Marker)IBA 02/2003

Therapy/Procedure

2	Therapeutics 01/2009 - 06/2004
2	Lasers (Laser) 12/2003 - 02/2003
1	Aftercare (After-Treatment) 02/2003
1	Induced Hyperthermia (Thermotherapy) 02/2003